CBDG — THC Farmaceuticals Income Statement
0.000.00%
Last trade - 00:00
HealthcareHighly SpeculativeMicro Cap
- $0.20m
- $0.11m
- $0.01m
2013 September 30th | 2014 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | ARS | PROSPECTUS | PROSPECTUS |
Standards: | USG | USG | — | — | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.022 | 0.019 | 0.008 | 0.002 | 0.01 |
Cost of Revenue | |||||
Gross Profit | — | — | 0.008 | 0.002 | 0.01 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.041 | 0.043 | 0.128 | 0.02 | -0.416 |
Operating Profit | -0.02 | -0.024 | -0.121 | -0.018 | 0.426 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.024 | -0.031 | -0.121 | -0.017 | 0.426 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.024 | -0.031 | -0.121 | -0.017 | 0.426 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -0.024 | -0.031 | -0.06 | -0.008 | 0.427 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -0.024 | -0.031 | -0.06 | -0.008 | 0.427 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.003 | -0.003 | 0.002 | -0 | -0 |
Dividends per Share |